Last updated: October 29, 2026
Gralise is an extended-release gabapentin product marketed by Assertio Holdings for postherpetic neuralgia. Its commercial value comes from once-daily dosing and a differentiated delivery profile rather than from gabapentin’s underlying pharmacology, which is widely available as a low-cost generic. Gralise remains commercially relevant, but its growth ceiling is limited by generic gabapentin competition, payer substitution, a narrow approved indication, and the absence of separately disclosed current revenue in Assertio’s public filings.
What is Gralise and how does it compete in the gabapentin market?
Gralise contains gabapentin and is approved for the management of postherpetic neuralgia in adults. The product uses an extended-release formulation taken once daily with the evening meal. The FDA-approved titration schedule reaches 1,800 mg once daily by Day 15 for patients who tolerate treatment (U.S. Food and Drug Administration, 2011).
| Product |
Active ingredient |
Dosage form |
Approved use |
Dosing profile |
Primary competitive issue |
| Gralise |
Gabapentin |
Extended-release tablet |
Postherpetic neuralgia |
Once daily with evening meal |
Generic gabapentin substitution |
| Neurontin and generics |
Gabapentin |
Immediate-release capsule, tablet, solution |
Multiple seizure and pain-related uses |
Usually divided doses |
Very low generic pricing |
| Horizant |
Gabapentin enacarbil |
Extended-release tablet |
PHN and restless legs syndrome |
Once or twice daily depending on indication |
Competes on extended-release positioning |
| Lyrica and pregabalin generics |
Pregabalin |
Immediate- and extended-release forms |
Neuropathic pain and seizure disorders |
Once or twice daily |
Alternative mechanism and broad generic availability |
Gralise is not interchangeable with immediate-release gabapentin solely because both products contain gabapentin. The products differ in release technology, pharmacokinetics, administration instructions, and FDA labeling. In practice, however, prescribers and payers can treat generic immediate-release gabapentin as a lower-cost alternative for many patients.
The product’s commercial proposition is based on reduced dosing frequency and potentially improved convenience. The clinical and economic value is strongest in patients who benefit from once-daily administration or who have adherence problems with divided-dose gabapentin.
When did Gralise receive FDA approval and lose market exclusivity?
Gralise received FDA approval in January 2011 under NDA 022399. The approval covered postherpetic neuralgia in adults. It did not establish broad FDA approval for all neuropathic pain uses commonly associated with gabapentin.
The product’s regulatory exclusivity has expired. Gralise therefore depends primarily on listed patents, formulation differentiation, brand recognition, prescriber preference, and commercial contracting rather than on unexpired new chemical entity exclusivity.
| Milestone |
Date |
Commercial significance |
| FDA approval of Gralise NDA 022399 |
January 2011 |
Established the branded extended-release gabapentin product |
| Depomed commercial ownership |
2011-2018 |
Depomed developed and commercialized Gralise |
| Depomed acquired by Assertio predecessor |
2018 |
Gralise entered the Assertio portfolio |
| FDA approval of generic gabapentin immediate-release products |
Before Gralise approval |
Created a low-cost therapeutic substitute |
| NCE exclusivity |
Expired |
No current chemical-entity exclusivity barrier |
| Current protection |
Patent and formulation rights |
Depends on individual patent claims and ANDA litigation |
Assertio does not report Gralise as a separately identified growth product in the same manner as its major hospital and specialty products. Its public financial disclosures describe an integrated commercial portfolio, making precise current Gralise revenue and product-level margin analysis unavailable from consolidated filings alone (Assertio Holdings, 2024).
How has Gralise’s financial trajectory developed?
Gralise’s financial trajectory reflects a mature branded product rather than a high-growth launch asset. The product was commercialized during a period when specialty pharmaceutical companies could obtain premium pricing for differentiated formulations. Its revenue opportunity narrowed as payers emphasized generic gabapentin and as the clinical distinction between once-daily extended-release dosing and lower-cost immediate-release therapy became harder to monetize.
Depomed’s acquisition of Gralise was part of a broader strategy to build a branded pain and specialty pharmaceutical portfolio. Assertio inherited Gralise after its 2018 acquisition of Depomed. Assertio later reshaped its portfolio around products with stronger near-term commercial economics, including ROLVEDON, INDOCIN, CAMBIA, and SPRIX.
Public filings do not provide a consistently reported, standalone Gralise revenue series for the current Assertio period. The following conclusions are supported by the company’s reporting:
- Gralise is no longer the central revenue driver of Assertio.
- Assertio’s financial results are increasingly influenced by ROLVEDON and other commercial products.
- Gralise contributes portfolio revenue but has limited ability to materially change consolidated growth.
- Product-level revenue, gross margin, prescription volume, and net pricing cannot be calculated reliably from the consolidated annual reports.
Assertio reported $138.2 million in total product sales for 2023, compared with $111.3 million in 2022. The increase was driven principally by the broader portfolio and the contribution from ROLVEDON, not by a disclosed step-change in Gralise performance (Assertio Holdings, 2024).
| Financial factor |
Effect on Gralise |
| Large generic gabapentin base |
Caps price and volume growth |
| Once-daily formulation |
Supports premium positioning |
| Narrow PHN label |
Limits addressable market |
| Mature commercial product |
Reduces launch-stage growth potential |
| Assertio portfolio focus |
Lowers strategic priority relative to ROLVEDON |
| Formulation patent estate |
Can delay or complicate direct generic entry |
| Payer step therapy |
Increases switching to immediate-release gabapentin |
Gralise’s likely economic profile is a stable or declining branded-product contribution, with upside dependent on successful payer coverage, adherence-based positioning, and the timing of generic extended-release entry.
What patents protect Gralise?
Gralise protection is based on formulation and drug-delivery patents rather than a new chemical entity patent. Public patent records associate Gralise with Depomed-originated intellectual property covering controlled-release gabapentin compositions and dosing systems.
Relevant public patent families include:
| Patent family or patent number |
General subject matter |
Commercial relevance |
| U.S. Patent No. 8,778,363 |
Extended-release gabapentin formulation technology |
Supports once-daily product positioning |
| U.S. Patent No. 8,741,904 |
Controlled-release gabapentin composition and delivery concepts |
May create formulation barriers |
| U.S. Patent No. 9,192,644 |
Later-generation formulation or dosing claims |
Potentially relevant to ANDA certification |
| U.S. Patent No. 9,283,197 |
Gabapentin extended-release technology |
May extend protection beyond earlier formulation rights |
The operative analysis must distinguish between patent issuance, Orange Book listing, claim scope, patent-term adjustment, and enforceability. A patent number alone does not establish that all claims are valid, infringed, or enforceable against a particular ANDA applicant.
The most commercially important claims are those directed to:
- Controlled release of gabapentin over a defined time period.
- Dosage forms designed for once-daily administration.
- Release profiles that depend on fed-state administration.
- Specific polymer matrices or excipient combinations.
- Methods of treating postherpetic neuralgia using the extended-release formulation.
Manufacturing patents can also matter if an ANDA applicant relies on substantially similar polymer systems, granulation processes, coating methods, or release-control techniques. Those patents may create operational risk even when the applicant designs around the principal composition claims.
What is the Orange Book status of Gralise?
The FDA Orange Book is the primary source for determining which patents are listed against the Gralise NDA and the corresponding expiration information. Orange Book-listed patents can trigger Paragraph IV certification and related Hatch-Waxman litigation.
The practical Orange Book questions are:
- Which patents were listed against NDA 022399?
- Which listed patents remain unexpired?
- Which patents contain claims that cover the proposed generic product?
- Did the generic applicant certify Paragraph IV, Paragraph III, or that no certification was required?
- Did the NDA holder file suit within 45 days of receiving a Paragraph IV notice?
The presence of a patent in the Orange Book does not guarantee a 30-month stay. A stay depends on statutory timing, the certification, timely litigation, and the number of qualifying patents involved. The FDA’s Orange Book should be reviewed together with the FDA product-specific guidance, ANDA approval status, and federal court docket records (U.S. Food and Drug Administration, 2024a, 2024b).
Are there Paragraph IV challenges to Gralise?
Generic applicants seeking approval before expiration of listed patents may submit Paragraph IV certifications alleging that the patents are invalid, unenforceable, or not infringed. A Paragraph IV notice can create immediate litigation exposure for Assertio and can delay final ANDA approval if the statutory requirements for a 30-month stay are met.
The principal risk indicators for Gralise are:
| Risk indicator |
Implication |
| Multiple formulation patents |
Applicants may challenge different claim sets |
| Narrow PHN indication |
A skinny-label strategy may reduce method-of-use risk |
| Generic gabapentin expertise |
Several manufacturers have formulation and regulatory capabilities |
| Mature product |
Commercial incentive rises as branded sales decline |
| Limited standalone disclosure |
External parties cannot easily estimate product-specific exposure |
| Possible patent settlements |
Entry could occur before nominal patent expiration |
A generic applicant may pursue a product that avoids a patented method of use while relying on non-infringing formulation claims. This creates a potential "skinny label" pathway under the Hatch-Waxman framework. The commercial effect depends on whether pharmacies, payers, and prescribers substitute the generic product for the branded product despite label differences.
No conclusion about a specific Paragraph IV challenge should be drawn without matching the ANDA applicant, certification date, patent list, and docketed litigation. The relevant public sources are FDA Orange Book records, FDA approval letters, PACER litigation records, and company securities filings.
Which companies could challenge Gralise?
The most plausible challengers are generic manufacturers with experience in modified-release oral solids, gabapentin products, and ANDA litigation. Potential participants in the competitive field include large generic companies such as Teva, Viatris, Sandoz, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Zydus Lifesciences, and Amneal Pharmaceuticals.
The competitive threat is not limited to a single direct generic. A manufacturer can enter through:
- An AB-rated extended-release gabapentin tablet.
- A formulation that avoids particular listed patents.
- A product with a restricted label.
- A licensing or settlement arrangement.
- An authorized-generic or branded-generic commercialization agreement.
The degree of substitution will depend on whether the generic is therapeutically and pharmaceutically substitutable under state pharmacy laws, whether payers place it on preferred tiers, and whether the product matches Gralise’s dosage strength and administration instructions.
What generic launch scenarios exist for Gralise?
Scenario 1: No direct extended-release generic
Gralise remains exposed to immediate-release gabapentin but retains a premium niche among patients who value once-daily dosing. Revenue declines gradually through payer pressure and switching rather than through an abrupt patent cliff.
Scenario 2: Single generic entrant
A first approved generic receives favorable formulary placement. Net price falls quickly, but the first entrant may not immediately eliminate all brand demand. Assertio could retain a specialty segment through contracting and adherence messaging.
Scenario 3: Multiple generic entrants
Several manufacturers enter after patent resolution or settlement. Price erosion accelerates, pharmacy substitution increases, and branded Gralise revenue becomes primarily residual.
Scenario 4: Litigation settlement with delayed entry
Assertio or a licensee agrees to a future generic entry date. The settlement preserves revenue through the agreed period but reduces the value of remaining patent term.
Scenario 5: Formulation patent survives challenge
A successful patent defense delays direct extended-release competition. This would improve Gralise’s revenue durability, but it would not eliminate substitution from immediate-release gabapentin.
How strong is the Gralise patent estate?
The estate is moderate rather than absolute.
Strengths include:
- Protection directed to a differentiated extended-release formulation.
- Multiple formulation and dosing patent families.
- A product with a clear technical distinction from immediate-release gabapentin.
- Potential manufacturing complexity involving release-control systems.
Weaknesses include:
- No current NCE exclusivity.
- A widely available and inexpensive active ingredient.
- Potential design-around opportunities.
- A narrow FDA-approved indication.
- The possibility of skinny-label generic marketing.
- Declining commercial value that can reduce litigation incentives.
The strongest claims are likely those requiring a specific release profile, formulation architecture, or pharmacokinetic performance. Broad claims covering gabapentin extended release generally face greater validity and design-around pressure.
What licensing deals affect Gralise?
Gralise originated with Depomed and is now part of Assertio’s inherited commercial portfolio. Public company disclosures have not established a major current third-party licensing transaction that materially changes Gralise’s standalone economics.
Earlier commercialization arrangements and portfolio transfers matter because they may affect:
- Royalty obligations.
- Transfer pricing.
- Manufacturing rights.
- Territory restrictions.
- Sublicensing rights.
- Litigation control.
- Post-expiration economics.
The absence of a separately identified current Gralise licensing stream limits external analysis of product-level margins and royalty-adjusted cash flow.
What is the geographic coverage of Gralise?
Gralise’s principal commercial value is in the United States, where its FDA approval, Orange Book listing, payer system, and Hatch-Waxman framework apply. Patent coverage and regulatory status outside the United States can differ materially.
| Region |
Key issue |
| United States |
FDA approval, Orange Book patents, ANDA pathway |
| European Union |
Separate regulatory and patent analysis; no automatic U.S. approval effect |
| Canada |
Distinct approval, patent, and substitution rules |
| Japan |
Separate clinical and regulatory requirements |
| Emerging markets |
Greater pressure from generic gabapentin and lower pricing |
U.S. patent expiry does not automatically determine foreign entry timing. Foreign commercialization depends on national patent rights, local approval requirements, compulsory-license rules, and distributor economics.
What is the revenue exposure and investment outlook for Gralise?
Gralise is unlikely to be a primary valuation driver for Assertio compared with products that have stronger growth, higher hospital adoption, or clearer commercial expansion. Its financial importance is best assessed through four variables:
- Net product sales after rebates and discounts.
- Prescription volume and refill persistence.
- Generic extended-release entry timing.
- Contribution margin after selling, marketing, royalty, and manufacturing costs.
The product can remain cash generative as a mature branded therapy if manufacturing costs are controlled and payer access remains adequate. Its downside is sharper if an AB-rated generic gains preferred formulary status. Its upside is limited because immediate-release gabapentin provides a highly credible low-cost alternative.
Key Takeaways
- Gralise is a once-daily extended-release gabapentin product approved for postherpetic neuralgia.
- Its main differentiation is formulation and dosing convenience, not active-ingredient novelty.
- NCE exclusivity has expired, leaving patent and commercial protection as the primary barriers.
- Assertio does not separately disclose a complete current Gralise revenue series.
- Gralise is a mature portfolio product and is not the main driver of Assertio’s recent growth.
- The key competitive threat is direct extended-release generic entry, combined with substitution from immediate-release gabapentin.
- Formulation patents can delay competition but may face invalidity, noninfringement, and design-around challenges.
- The most important diligence sources are the FDA Orange Book, Assertio SEC filings, FDA ANDA records, and federal court dockets.
FAQs About Gralise Market and Patent Risk
Is Gralise the same as generic gabapentin?
No. Both contain gabapentin, but Gralise is an extended-release tablet with once-daily administration, while most generic gabapentin products are immediate-release and taken in divided doses.
Does Gralise have new chemical entity exclusivity?
No. Gralise was approved in 2011, and its regulatory protection is now based primarily on formulation patents and commercial differentiation.
Can a generic manufacturer launch gabapentin without infringing Gralise patents?
Potentially. An applicant may design around formulation claims, use a different release system, or pursue a restricted label. The outcome depends on the exact ANDA formulation and the claims of the listed patents.
Why does Gralise retain value despite cheap generic gabapentin?
Its value comes from once-daily dosing, an extended-release delivery profile, and use in patients who may prefer or respond better to the branded regimen. That value is constrained by payer substitution and the availability of immediate-release gabapentin.
Is Gralise material to Assertio’s valuation?
Gralise contributes to Assertio’s branded portfolio, but public filings indicate that recent consolidated performance is driven more heavily by products such as ROLVEDON and other commercial assets. Gralise is more likely to affect portfolio durability than overall company growth.
References
Assertio Holdings, Inc. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.
U.S. Food and Drug Administration. (2011). Gralise prescribing information, NDA 022399.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024b). Patent and exclusivity information for approved drug products.
U.S. Patent and Trademark Office. (2024). Patent Center and patent information for gabapentin extended-release formulation patents.
